Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: The clinical usefulness of subcutaneous allergen immunotherapy (SCIT) in the treatment of atopic dermatitis (AD) is still controversial. We analyzed the clinical efficacy of SCIT in patients with AD and the clinical characteristics of patients showing a favorable clinical response to the treatment. Materials and Methods: Two hundred and fifty one patients with AD sensitized to house dust mite (HDM) were treated by SCIT using HDM extract. The clinical severity of AD was measured using the standardized clinical severity scoring system for AD (SCORAD)at baseline and 12 months. A favorable clinical response to SCIT was defined as a decrease in SCORAD value at 12 months greater than 50% compared to baseline value. Severe AD was defined as a baseline SCORAD value above 50. Results: A favorable clinical response to SCIT was observed in 73.6% of patients. The proportion of patients showing a favorable clinicalresponse to SCIT was significantly higher in patients with severe AD (90.6%) than patients with mild to moderated AD (63.7%) (p<0.001). Patients with severe AD showing a favorable clinical response had a significantly shorter duration of AD (12.3±8.5 years; mean±SD) than patients with severe AD showing no significant clinical response (20.6±10.9 years) (p<0.05) at baseline. Conclusion: SCIT could be a clinically useful therapeutic option for patients with severe AD sensitized to HDM. Early initiation of SCIT might provide a favorable clinical outcome in patients with severe AD sensitized to HDM.
Abstract
Purpose: The clinical usefulness of subcutaneous allergen immunotherapy (SCIT) in the treatment of atopic dermatitis (AD) is still controversial. We analyzed the clinical efficacy of SCIT in patients with AD and the clinical characteristics of patients showing a favorable clinical response to the treatment. Materials and Methods: Two hundred and fifty one patients with AD sensitized to house dust mite (HDM) were treated by SCIT using HDM extract. The clinical severity of AD was measured using the standardized clinical severity scoring system for AD (SCORAD)at baseline and 12 months. A favorable clinical response to SCIT was defined as a decrease in SCORAD value at 12 months greater than 50% compared to baseline value. Severe AD was defined as a baseline SCORAD value above 50. Results: A favorable clinical response to SCIT was observed in 73.6% of patients. The proportion of patients showing a favorable clinicalresponse to SCIT was significantly higher in patients with severe AD (90.6%) than patients with mild to moderated AD (63.7%) (p<0.001). Patients with severe AD showing a favorable clinical response had a significantly shorter duration of AD (12.3±8.5 years; mean±SD) than patients with severe AD showing no significant clinical response (20.6±10.9 years) (p<0.05) at baseline. Conclusion: SCIT could be a clinically useful therapeutic option for patients with severe AD sensitized to HDM. Early initiation of SCIT might provide a favorable clinical outcome in patients with severe AD sensitized to HDM.
참고문헌 (24)
- Akdis CA, "Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology", American Academy of Allergy, Asthma and Immunology, J Allergy Clin Immunol, pp.2006, 118[DOI]
- Bieber T, "Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine", Allergy, 67, pp.1475~1482 (2012)
- 남동호, "Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist’s View", Annals of Dermatology, 27(4), pp.355~363 (2015), 대한피부과학회
- Beck LA, "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis", N Engl J Med, 371, pp.130~139 (2014)
- 남동호, "Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: A Preliminary Report", Allergy, Asthma & Immunology Research, 6(1), pp.89~94 (2014), 대한천식알레르기학회
- Nahm DH, "Effects of intramuscular injection of autologous immunoglobulin on clinical severity and serum IgE concentration in patients with atopic dermatitis", Dermatology, 231, pp.145~151 (2015)
- Bousquet J, "Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper", J Allergy Clin Immunol, 102, pp.558~562 (1998)
- Pipet A, "Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of effcacy", Respir Med, 103, pp.800~812 (2009)
- Bae JM, "Effcacy of allergenspecific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials", J Allergy Clin Immunol, 132, pp.110~117 (2013)
- Hanifin JM, "Diagnostic features of atopic eczema", Acta Derm Venereol Suppl (Stockh), 92(Suppl), pp.S44~S47 (1980)
- 김명은, "Safety of Accelerated Schedules of Subcutaneous Allergen Immunotherapy with House Dust Mite Extract in Patients with Atopic Dermatitis", Journal of Korean Medical Science, 26(9), pp.1159~1164 (2011), 대한의학회
- Nahm DH, "Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex", Int Arch Allergy Immunol, 146, pp.235~240 (2008)
- 남동호, "Treatment of Severe Atopic Dermatitis with a Combination of Subcutaneous Allergen Immunotherapy and Cyclosporin", Yonsei Medical Journal, 53(1), pp.158~163 (2012), 연세대학교의과대학
- "European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: the SCORAD index", Dermatology, 186, pp.23~31 (1993)
- Oranje AP, "Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score", Br J Dermatol, 157, pp.645~648 (2007)
- Canonica GW, "Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce", Allergy, 62, pp.317~324 (2007)
- Novak N, "Effcacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis", J Allergy Clin Immunol, 130, pp.925~931 (2012)
- Kang MS, "The effect and prediction of effcacy of immunotherapy with mixed-allergen extracts in respiratory allergy patients", Korean J Med, 42, pp.297~305 (1992)
- 이광훈, "Retrospective Analysis on the Effects of House Dust Mite Specific Immunotherapy for More Than 3 Years in Atopic Dermatitis", Yonsei Medical Journal, 57(2), pp.393~398 (2016), 연세대학교의과대학[DOI]
- Bieber T, "Atopic dermatitis", N Engl J Med, 358, pp.1483~1494 (2008)
- Tang TS, "Does “autoreactivity” play a role in atopic dermatitis?", J Allergy Clin Immunol, 129, pp.1209~1215 (2012)
- Li Q, "Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis", Int Arch Allergy Immunol, 164, pp.210~217 (2014)
- 이정수, "Specific Immunotherapy in Atopic Dermatitis", Allergy, Asthma & Immunology Research, 7(3), pp.221~229 (2015), 대한천식알레르기학회
- 남동호, "Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: Long-Term Changes of Clinical Severity and Laboratory Parameters", Allergy, Asthma & Immunology Research, 8(4), pp.375~382 (2016), 대한천식알레르기학회